ICM
XERS icon

Invenomic Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Invenomic Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-592,078
Closed -$1.33M – 183
2024
Q2 		$1.33M Sell
592,078
-12,434
-2% -$25.1K 0.06% 154
2024
Q1 		$1.34M Buy
604,512
+35,893
+6% +$92.9K 0.07% 135
2023
Q4 		$1.34M Buy
+568,619
New +$1.05M 0.06% 155

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Invenomic Capital Management's XERS Position: Q3 2024 in Review

Invenomic Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2024, closing a stake of 592,078 shares — an estimated $1.33M sold.

Invenomic Capital Management first reported a position in XERS in Q4 2023 and held it in 3 quarters. The position peaked at $1.34M in Q4 2023. 144 funds tracked by Wall St. Rank hold XERS as of Q3 2024.

  • Invenomic Capital Management reported no remaining Xeris Biopharma Holdings position as of Q3 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 592,078 Xeris Biopharma Holdings shares in Q3 2024, an estimated $1.33M.
  • Invenomic Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2023 and held it in 3 quarters.
  • Invenomic Capital Management's Xeris Biopharma Holdings position peaked at $1.34M in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2024.

Based on Invenomic Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.